Endocrine, metabolic & immune disorders drug targets
April 29, 2025
Meng Wang, Qian Ma, Wenjuan Wang et al.
1 citation
Esketamine reduced acute lung injury caused by limb ischemia-reperfusion in a rat model. Treatment lowered pulmonary edema, inflammatory cell infiltration, and oxidative stress, as shown by decreased MDA and increased SOD levels. It also reduced inflammatory cytokines in bronchoalveolar fluid and serum. The protective effect involved suppression of the TLR4/NF-κB/NLRP3 pathway; activating that pathway with LPS reversed esketamine's benefits. The findings suggest esketamine may be a potential therapy for acute lung injury.
Frontiers in neurology
January 1, 2025
Wenjia He, Xinyu Lyu, Hui Zhang et al.
In people with benign paroxysmal positional vertigo (BPPV), resting-state functional connectivity (FC) between brain regions involved in vestibular, motor, and sensory processing is abnormally elevated compared to healthy controls. After a canalith repositioning maneuver, whole-brain average FC strength decreased significantly, and connectivity between specific region pairs—including prefrontal cortex, occipital cortex, middle temporal gyrus, motor cortex, and somatosensory cortex—returned to normal levels. Clinical symptoms also improved: the Dizziness Handicap Inventory score dropped by 23.4% and the Visual Analogue Scale score showed a significant reduction. The findings suggest BPPV involves compensatory enhancement of the vestibulo-sensorimotor network, and that repositioning therapy restores pathologically enhanced FC to normal, supporting functional near-infrared spectroscopy as a potential objective biomarker for evaluating BPPV neural mechanisms and treatment efficacy.